TAKE THIS POLL |
|
|
- Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML 19 Nov 2009 15:40 GMT
... Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) MONTREAL , Nov. 19 /PRNewswire/ - Aegera Therapeutics Inc. announced today the dosing ...
- Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) (PRN) 19 Nov 2009 15:10 GMT
... "Strong demonstration of activity in our non-randomized Phase 2A study conducted in this indication have encouraged us ...
- Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) (CNW) 19 Nov 2009 15:10 GMT
... "Strong demonstration of activity in our non-randomized Phase 2A study conducted in this indication have encouraged us ...
- Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 19 Nov 2009 15:11 GMT
... MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeutics Inc. announced today the dosing of the first patient in a ...
- Synta Presents Preclinical Data on Next Generation Hsp90 Inhibitor, STA-9090 18 Nov 2009 13:31 GMT
... (GIST), prostate cancer, colon cancer, breast cancer, gastric cancer, pancreatic cancer, colon cancer, melanoma, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, B-cell lymphoma, and multiple myeloma. Potent activity was ...
- Sunesis Reports Financial Results for the Third Quarter of 2009 16 Nov 2009 13:34 GMT
... 2009. Sunesis also announced that two abstracts related to the voreloxin clinical program in Acute Myeloid Leukemia (AML) have been accepted for presentation at the 51st Annual Meeting of the American ...
- Cyclacel Pharmaceuticals to Present Sapacitabine Phase 2 AML & MDS Data at the Upcoming American Society of Hematology Meeting 17 Nov 2009 12:31 GMT
... Relapse Date/Time: Saturday, December 5, 2009, 5:30 PM - 7:30 PM Central Time Session: Acute Myeloid Leukemia - Therapy, excluding Transplantation Poster I Poster board: I-83 Abstract: 1758 Title: A Randomized ...
- Cyclacel Pharmaceuticals to Present Sapacitabine Phase 2 AML & MDS Data at the Upcoming American Society of Hematol 17 Nov 2009 12:32 GMT
... Relapse Date/Time: Saturday, December 5, 2009, 5:30 PM - 7:30 PM Central Time Session: Acute Myeloid Leukemia - Therapy, excluding Transplantation Poster I Poster board: I-83 Abstract: 1758 Title: A Randomized ...
- Cyclacel Pharmaceuticals to Present Sapacitabine Phase 2 AML & MDS Data at the Upcoming American Soc 17 Nov 2009 12:32 GMT
... Relapse Date/Time: Saturday, December 5, 2009, 5:30 PM - 7:30 PM Central Time Session: Acute Myeloid Leukemia - Therapy, excluding Transplantation Poster I Poster board: I-83 Abstract: 1758 Title: A Randomized ...
- Health: Terra med Alliance News Two Units of Umbilical Cord Blood Reduce Risk of Leukemia 19 Nov 2009 02:31 GMT
... study was 16 years. Eighty-eight patients had acute lymphoblastic leukemia (ALL) and 89 had acute myeloid leukemia (AML). "Our analysis showed that patients in first or second remission from the leukemia ...
- U of M researchers find 2 units of umbilical cord blood reduce risk of leukemia recurrence 14 Nov 2009 00:52 GMT
... study was 16 years. Eighty-eight patients had acute lymphoblastic leukemia (ALL) and 89 had acute myeloid leukemia (AML). "Our analysis showed that patients in first or second remission from the leukemia ...
- 2 Units Of Umbilical Cord Blood Reduce Risk Of Leukemia Recurrence 14 Nov 2009 15:34 GMT
... study was 16 years. Eighty-eight patients had acute lymphoblastic leukemia (ALL) and 89 had acute myeloid leukemia (AML). "Our analysis showed that patients in first or second remission from the leukemia ...
- AACR-NCI-EORTC conference highlights major expansion in cancer drug pipeline 17 Nov 2009 11:16 GMT
... bodes well for future drug discovery efforts," said McDermott. Cells from 51 patients with acute myeloid leukemia (AML) and 12 patients with chronic myelogenuous leukemia (CML) were screened with one of ...
- Two units of UCB reduce risk of leukemia from returning, shows new study 16 Nov 2009 07:16 GMT
... study was 16 years. Eighty-eight patients had acute lymphoblastic leukemia (ALL) and 89 had acute myeloid leukemia (AML). "Our analysis showed that patients in first or second remission from the leukemia ...
- Finding May Give Hope To More Leukemia Patients So They May Live Cancer-Free 16 Nov 2009 09:11 GMT
... study was 16 years. Eighty-eight patients had acute lymphoblastic leukemia (ALL) and 89 had acute myeloid leukemia (AML). "Our analysis showed that patients in first or second remission from the leukemia ...
- www.StockMarketingInc.com: Take a Look Now!! PSGI - Prime Star Group, Inc. :: Sign Up For The Hottest Newsletter Out There!! 17 Nov 2009 10:56 GMT
... for the Phase 1 clinical study with ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML) were presented by principal investigator, Dr. Karen Yee, at the AACR-NCI-EORTC International Conference ...
- Lipoxen plc New Research Collaboration with Pharmsynthez 17 Nov 2009 13:32 GMT
... Pharmsynthez’s compounds in multiple sclerosis, HIV and non-Hodgkin lymphoma as well as cystic fibrosis, acute myeloid leukemia and type 2 diabetes. Given that the commitment of upfront resources is limited to ...
- Synta Presents Preclinical Data on Next Generation Hsp90 Inhibitor, STA-9090 - Broad anti-cancer activity as a single agent and in combination 18 Nov 2009 13:30 GMT
... (GIST), prostate cancer, colon cancer, breast cancer, gastric cancer, pancreatic cancer, colon cancer, melanoma, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, B-cell lymphoma, and multiple myeloma. Potent activity was ...
- Two Units Of Umbilical Cord Blood Reduce Risk Of Leukemia Recurrence 14 Nov 2009 16:13 GMT
... study was 16 years. Eighty-eight patients had acute lymphoblastic leukemia (ALL) and 89 had acute myeloid leukemia (AML). "Our analysis showed that patients in first or second remission from the leukemia ...
- Advances in Molecular Drug Development Highlighted 16 Nov 2009 20:13 GMT
... bodes well for future drug discovery efforts," said McDermott. Cells from 51 patients with acute myeloid leukemia (AML) and 12 patients with chronic myelogenuous leukemia (CML) were screened with one of ...
- EntreMed's ENMD-2076 Active in Solid and Hematological Cancers 16 Nov 2009 17:50 GMT
... for the Phase 1 clinical study with ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML) were presented by principal investigator, Dr. Karen Yee, at the AACR-NCI-EORTC International Conference ...
- EntreMed's ENMD-2076 Active in Solid and Hematological Cancers (PRN) 16 Nov 2009 17:50 GMT
... for the Phase 1 clinical study with ENMD-2076 in patients with relapsed or refractory acute myeloid leukemia (AML) were presented by principal investigator, Dr. Karen Yee, at the being held this ...
- Synta Presents Preclinical Data on Next Generation Hsp90 Inhibitor, STA-9090 (BIZ) 18 Nov 2009 13:30 GMT
... as non-small cell lung cancer, gastric carcinoma and melanoma and hematologic malignancies such as acute myeloid leukemia, B-cell lymphoma, chronic myeloid leukemia and multiple myeloma. Activity was demonstrated in models that ...
- Three Distinct Domains Contribute to Nuclear Transport of Murine Foxp3 22 Nov 2009 10:35 GMT
... domain (FHD), recently reported to be a binding site for the runt-related transcription factor 1/acute myeloid leukemia 1 (Runx1/AML1). The third domain (Domain 3) is located within the N-terminal first 51 ...
- Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 22 Nov 2009 19:02 GMT
... mutation was also shown to be present in a significant percentage of patients with Acute Myeloid Leukemia, another devastating disease. The insight from this new research at Agios is the first ...
1 - 25 of 93 next >
Powered by 
News by PR Newswire
24-7 pressrelease
Emailwire
|